Similarly, engineering the NK-like lymphoma cell line NK92 with an anti-CD19 CAR significantly increased in vitro cytotoxicity and prominently induced apoptosis in rituximab- and obinutuzumab-resistant cell lines and patient-derived cells, and delayed tumor growth in B-NHL xenografts [86]. Here, CD19 is linked to lymphoma.